Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Last trade $16.52
Day change +$0.62 (+3.90%)
Day range $15.66 – $16.65
Volume 2,987,098
Market cap $1.62B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.62B
Price / earnings
—
Price / book
-4.31×
Price / sales
2.22×
EV / sales
2.01×
EV / EBITDA
-3.39×

Profitability

Earnings per share
-$5.14
Return on assets
-44.11%
Return on equity
139.24%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
1.4×
Quick ratio
1.25×
Cash ratio
0.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$441.77M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RARE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$173M$214M$136M$207.28M$160M$167M$139M$164.65M
Cost of revenue$32M$34M$30M$29.35M$28M$23M$29M$17.17M
Gross profit$141M$180M$106M$177.93M$132M$144M$110M$147.48M
Selling, general and administrative$97M$88M$88M$87.94M$87M$87M$87M$81.89M
Research and development$154M$167M$187M$203.28M$216M$165M$166M$187.9M
Total operating expenses$251M$255M$275M$291.22M$303M$252M$253M$269.79M
Operating income-$110M-$75M-$169M-$113.28M-$171M-$108M-$143M-$122.31M
Interest expense-$20M-$22M-$21M-$19.47M-$14M-$14M-$14M-$15.48M
Income before taxes-$127M-$91M-$184M-$127.69M-$179M-$114M-$150M-$132.82M
Income taxes-$9M$1M$1M$870K$1M$1M$1M$384K
Net income-$118M-$92M-$185M-$128.56M-$180M-$115M-$151M-$133.2M
Net income attributable to common shareholders-$118M-$92M-$185M-$128.56M-$180M-$115M-$151M-$133.2M
EBITDA-$101M-$67M-$161M-$104.5M-$163M-$99M-$134M-$112.77M
Basic earnings per share-$1.16-$0.90-$1.84-$1.29-$1.81-$1.17-$1.57-$1.39
Diluted earnings per share-$1.16-$0.90-$1.84-$1.29-$1.81-$1.17-$1.57-$1.39

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Ultragenyx announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111), an investigational gene therapy for MPS IIIA (Sanfilippo syndrome Type A). The company has also coordinated with NICE to align the evaluation timeline with the regulatory review process. The therapy received FDA approval in September 2026 and is also under review by the European Medicines Agency.

Zacks Investment Research

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Ultragenyx (RARE) reported a quarterly loss of $1.16 per share, slightly missing the consensus estimate of $1.15, with revenues of $173 million falling 6.11% short of expectations. Despite underperforming the market by 29.1% year-to-date, the stock maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 44% of sectors.

Zacks Investment Research

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

Ultragenyx reported Q3 2026 revenue of $173 million, up 8.2% year-over-year but missing the consensus estimate of $184.25 million by 6.11%. EPS improved to -$1.16 from -$1.81 a year ago, slightly beating the -$1.15 estimate. Key product revenues showed mixed results: Dojolvi and Evkeeza exceeded expectations with strong growth, while Crysvita revenue fell short of estimates. The stock has gained 12.4% over the past month and holds a Zacks Rank #2 (Buy) rating.

Zacks Investment Research

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for

Cytek Biosciences is expected to report a year-over-year earnings decline with higher revenues when it releases Q3 2026 results on November 4. The company is projected to post a quarterly loss of $0.08 per share with revenues of $52.9 million (up 1.2% YoY). With an Earnings ESP of 0% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has failed to beat consensus EPS estimates in the last four quarters.

Zacks Investment Research

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

GlaxoSmithKline (GSK) reported quarterly earnings of $1.47 per share, beating consensus estimates of $1.40 and delivering a 5% earnings surprise. Revenue of $11.95 billion also exceeded expectations by 1.24%. However, GSK shares have gained only 3.9% year-to-date versus the S&P 500's 12.8% gain. The stock maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.